Introduction
rheumatoid arthritis, RA, tumor necrosis
RHEUMATOID ARTHRITIS, DISEASE, TUMOR NECROSIS
In the past 20 years, the availability of tumor necrosis factor inhibitors (TNFis) and other biologic disease-modifying antirheumatic drugs (bDMARDs) has transformed treatment for patients with rheumatoid arthritis (RA). More recently, targeted synthetic DMARDs (tsDMARDs), including janus kinase inhibitors (JAKis), have become available and are considered equivalent to bDMARDs for patients with moderate to severe disease refractory to conventional synthetic DMARD (csDMARD) therapy.Although trials directly comparing specific b/tsDMARDs head-to-head are limited, a double-blind phase 3b/4 randomized clinical trialRegistries and real-world data sets (RWDs), which include routinely collected data such as electronic medical records (EMRs) and medical claims data, are a valuable source of information for understanding the effectiveness of treatments. There is increasing recognition of the complementary role for real-world evidence based on analyses of RWDs in health care and regulatory decision-making.Target trial emulation (TTE) is a framework for comparative effectiveness analyses whereby principles from the design of randomized clinical trials (RCTs) are applied to observational research by making explicit the design of the trial that is intended to be emulated.